MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413644 | Name: APL 180

Description:

WARNING: This product is for research use only, not for human or veterinary use.

APL 180 is an ApoA1 mimetic that is administered by intravenous infusion, for the treatment of coronary heart disease.

Chemical Structure

APL 180
APL 180
CAS# 388566-97-0

Theoretical Analysis

MedKoo Cat#: 413644

Name: APL 180

CAS#: 388566-97-0

Chemical Formula: C114H156N24O28

Exact Mass: 2309.1521

Molecular Weight: 2310.64

Elemental Analysis: C, 59.26; H, 6.81; N, 14.55; O, 19.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
APL 180; APL180; APL-180; DF4; DF-4; DF 4; L4F; L-4F; L 4F
IUPAC/Chemical Name
L-Phenylalaninamide, N-acetyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-lysyl-L-alanyl-L-phenylalanyl-L-tyrosyl-L-alpha-aspartyl-L-lysyl-L-valyl-L-alanyl-L-alpha-glutamyl-L-lysyl-L-phenylalanyl-L-lysyl-L-alpha-glutamyl-L-alanyl-
InChi Key
ZKKBZMXTFBAQLP-PINGPBTISA-N
InChi Code
InChI=1S/C114H156N24O28/c1-64(2)96(114(166)123-67(5)98(150)125-83(48-50-93(143)144)105(157)126-80(41-23-27-53-117)104(156)133-86(57-71-33-15-9-16-34-71)107(159)128-79(40-22-26-52-116)103(155)130-82(47-49-92(141)142)102(154)122-65(3)99(151)131-84(97(119)149)55-69-29-11-7-12-30-69)138-106(158)81(42-24-28-54-118)129-113(165)91(62-95(147)148)137-110(162)88(59-73-43-45-75(140)46-44-73)134-109(161)85(56-70-31-13-8-14-32-70)132-100(152)66(4)121-101(153)78(39-21-25-51-115)127-108(160)87(58-72-35-17-10-18-36-72)135-111(163)89(60-74-63-120-77-38-20-19-37-76(74)77)136-112(164)90(61-94(145)146)124-68(6)139/h7-20,29-38,43-46,63-67,78-91,96,120,140H,21-28,39-42,47-62,115-118H2,1-6H3,(H2,119,149)(H,121,153)(H,122,154)(H,123,166)(H,124,139)(H,125,150)(H,126,157)(H,127,160)(H,128,159)(H,129,165)(H,130,155)(H,131,151)(H,132,152)(H,133,156)(H,134,161)(H,135,163)(H,136,164)(H,137,162)(H,138,158)(H,141,142)(H,143,144)(H,145,146)(H,147,148)/t65-,66-,67-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,96-/m0/s1
SMILES Code
O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC([C@H](CC2=CC=CC=C2)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC3=CC=C(O)C=C3)NC([C@H](CC4=CC=CC=C4)NC([C@H](C)NC([C@H](CCCCN)NC([C@H](CC5=CC=CC=C5)NC([C@H](CC6=CNC7=C6C=CC=C7)NC([C@H](CC(O)=O)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,310.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2016 Feb;58(2):71-80. doi: 10.1111/ped.12865. PMID: 26645706. 2: Bala MM, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018 Jul 13;7(7):CD012534. doi: 10.1002/14651858.CD012534.pub2. PMID: 30004572; PMCID: PMC6513409. 3: Yedla RP, Bala SC, Pydi VR, Kuruva SP, Chennamaneni R, Konatam ML, Paul TR, Gundeti S. Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e158-e164. doi: 10.1016/j.clml.2019.12.011. Epub 2019 Dec 24. PMID: 31992504. 4: Liu CC, Schofield T, Tang A, Manzi S, Ahearn JM. Potential Roles of Antiphospholipid Antibodies in Generating Platelet-C4d in Systemic Lupus Erythematosus. Antibodies (Basel). 2017 Jul 2;6(3):9. doi: 10.3390/antib6030009. PMID: 31548524; PMCID: PMC6698828. 5: Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan HC, Garcés-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013 Mar 14;121(11):1935-43. doi: 10.1182/blood-2012-08-449918. Epub 2013 Jan 14. PMID: 23319575. 6: Fabrizi F, Sangiorgio R, Pontoriero G, Corti M, Tentori F, Troina E, Locatelli F. Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol. 1999 Mar-Apr;12(2):89-94. PMID: 10378664. 7: Shi JL, Li JM, Hou JX, Cao FL, Liu SC, Zhou J, Gao CY, Wang J, Tan XY, Li JN, Liu Y, Liu Y, Ma RS, Yang X. [Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells]. Zhonghua Yi Xue Za Zhi. 2012 Apr 24;92(16):1095-9. Chinese. PMID: 22781766. 8: Sumi D, Shinkai Y, Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol. 2010 May 1;244(3):385-92. doi: 10.1016/j.taap.2010.02.012. Epub 2010 Mar 1. PMID: 20193703. 9: Tøstesen M, Østgård LSG, Kjeldsen E, Stentoft J, Nørgaard JM. [Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion]. Ugeskr Laeger. 2018 Jan 15;180(3):V06170489. Danish. PMID: 29336300. 10: Adachi S. [Progress in the diagnosis and treatment of childhood AML]. Rinsho Ketsueki. 2015 Oct;56(10):2220-9. Japanese. doi: 10.11406/rinketsu.56.2220. PMID: 26458463.